MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$146.76
−0.27%Sep 18, 2026, 10:55 UTC
The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Merck's KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as perioperative treatment for adults with resectable muscle-invasive bladder cancer.
Source:Sep 17, 2026, 22:50 UTC
Merck shares closed at $147.17, up 1.56% from the prior trading session, outperforming the broader market.
Source:Sep 14, 2026, 14:15 UTC
Moderna and Merck announced that a personalized mRNA cancer vaccine combined with an immunotherapy drug succeeded in a late-stage trial for skin cancer.
Sep 14, 2026, 10:16 UTC
Perspective Therapeutics announced a clinical trial collaboration and supply agreement with Merck to evaluate [212Pb]PSV359 in combination with Keytruda (pembrolizumab) in FAP-α positive solid tumors.
Source:Sep 13, 2026, 13:30 UTC
The International Consortium of Investigative Journalists published the findings of its yearlong 'Cancer Calculus' investigation into global access to Merck & Co's cancer drug Keytruda.
Source:Sep 13, 2026, 01:45 UTC
Merck's Keytruda was evaluated as monotherapy and in combination with Trodelvy in the Merck-sponsored Evoke-03/Keynote-D46 phase 3 trial in previously untreated PD-L1-high non-small cell lung cancer, with results presented at the 2026 World Conference on Lung Cancer.
Source:Sep 12, 2026, 18:00 UTC
Tempus partnered with Merck on AI-driven precision medicine.
Source:Sep 11, 2026, 03:55 UTC
In US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.
Source:Sep 10, 2026, 21:50 UTC
Merck shares closed at $144.71 on the most recent trading day, falling 1.91% and underperforming the S&P 500's 0.59% decline.
Sep 10, 2026, 08:21 UTC
China's National Medical Products Administration approved Merck's Keytruda (pembrolizumab) for expanded use in early-stage high-risk triple-negative breast cancer in China.
Source:Sep 10, 2026, 07:00 UTC
MSD inaugurated a new 2.5 lakh sq. ft Technology Centre in Hitech City, Hyderabad, strengthening its global technology and digital capabilities network.
Source:Sep 9, 2026, 08:02 UTC
Merck announced the commercial launch in China of its RSV monoclonal antibody clerosavir (Anfuchang) for preventing RSV lower respiratory tract infections in newborns and infants.
Source:Sep 4, 2026, 00:42 UTC
Merck announced that China's National Medical Products Administration approved its PD-1 inhibitor Keytruda (pembrolizumab) for the neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma in adult patients with PD-L1 expression (CPS ≥1).
Source:Sep 3, 2026, 23:53 UTC
Electroninks, Merck, and Qualipoly Chemical formed a strategic partnership to build an advanced packaging ecosystem for semiconductor customers.
Source:Sep 3, 2026, 15:24 UTC
Cipla's U.S. unit entered an exclusive partnership with Qilu Pharmaceutical to license a biosimilar of Merck's Keytruda for the U.S. market.
Source:Aug 29, 2026, 21:30 UTC
The Australian Federal Government announced that KEYTRUDA (pembrolizumab) will be subsidised through the Pharmaceutical Benefits Scheme (PBS) for over 10,000 newly eligible Australians with advanced or metastatic cancers from 1 September 2026.
Aug 27, 2026, 20:45 UTC
The University of Queensland commemorates the 20th anniversary of the first dose of the HPV vaccine (Gardasil 9), developed by Ian Frazer and Jian Zhou, which has been administered over 600 million times worldwide and is credited with helping to end cervical cancer in Australia.
Source:Aug 26, 2026, 04:45 UTC
Four Democratic senators, led by Elizabeth Warren, sent a letter to Health Secretary Robert F. Kennedy Jr. questioning his disclosures regarding a $50 million settlement by Merck over Gardasil vaccine litigation, in which Kennedy had a financial interest before taking office.
Source:Aug 25, 2026, 09:21 UTC
Bank of New York Mellon Corp reduced its stake in Merck & Co., Inc. by 2.0% during the quarter, selling 373,190 shares, as disclosed in its Form 13F filing.
Source:Aug 25, 2026, 09:21 UTC
Bellars Harris Wealth Management LLC disclosed a new minority stake in Merck & Co., Inc. by purchasing 79,847 shares valued at approximately $10.26 million, as reported in its Form 13F filing.
Source:Aug 25, 2026, 07:57 UTC
ABN AMRO Bank N.V. reduced its stake in Merck & Co., Inc. by 7.6% during the quarter, selling 11,149 shares, according to its Form 13F filing.
Source:Aug 20, 2026, 06:48 UTC
Shares of CSPC Pharmaceutical Group surged over 15% in morning trading on August 20, 2026, driven by positive Phase 3 results of Moderna and Merck's personalized mRNA cancer therapy intismeran.
Source:Aug 19, 2026, 19:38 UTC
Biopharma stocks including AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and Merck rallied on Wednesday, with Merck jumping 12.4%.
Source:Aug 19, 2026, 10:46 UTC
Merck and Moderna announced that the Phase 3 clinical trial of Intismeran met its primary endpoint, showing the vaccine prevents melanoma recurrence.
Aug 16, 2026, 13:46 UTC
Merck reported first-half 2026 results with a net loss of $5.575 billion due to a one-time acquisition charge, and total revenue of $32.893 billion, up 5% year-over-year.
Source:Aug 15, 2026, 15:46 UTC
Richard R. DeLuca, Executive Vice President and President of Merck Animal Health, sold 45,320 shares of Merck & Co., Inc. common stock over three days from August 10 to August 12, 2026, totaling approximately $5,942,369.
Source:Aug 10, 2026, 18:57 UTC
President Trump is expected to sign an executive order recommending the split of the MMR combination vaccine into three separate vaccines and the administration of childhood vaccines at separate visits.
Aug 4, 2026, 10:30 UTC
Merck & Co., Inc. announced its financial results for the second quarter of 2026.
Page 1Next →